CN113425731B - 一种增效干细胞治疗心梗的药物及其应用 - Google Patents
一种增效干细胞治疗心梗的药物及其应用 Download PDFInfo
- Publication number
- CN113425731B CN113425731B CN202110700458.8A CN202110700458A CN113425731B CN 113425731 B CN113425731 B CN 113425731B CN 202110700458 A CN202110700458 A CN 202110700458A CN 113425731 B CN113425731 B CN 113425731B
- Authority
- CN
- China
- Prior art keywords
- myocardial infarction
- stem cells
- medicine
- application
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 57
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 210000000130 stem cell Anatomy 0.000 title abstract description 17
- 230000002195 synergetic effect Effects 0.000 title abstract description 10
- 229940079593 drug Drugs 0.000 title description 8
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 claims abstract description 32
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 19
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 230000004217 heart function Effects 0.000 claims description 7
- 230000004083 survival effect Effects 0.000 claims description 6
- 208000033774 Ventricular Remodeling Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000011133 mesenchymal stem cell therapy Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- VRYALKFFQXWPIH-RANCGNPWSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxy-2-tritiohexanal Chemical compound O=CC([3H])[C@@H](O)[C@H](O)[C@H](O)CO VRYALKFFQXWPIH-RANCGNPWSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002791 glucosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 210000000062 pectoralis major Anatomy 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000603 stem cell niche Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种增效干细胞治疗心梗的药物及其应用，具体为2‑脱氧‑D‑葡萄糖在制备增效干细胞治疗心梗的药物中的应用，动物实验证实，注射2‑脱氧‑D‑葡萄糖后，增加了注射间充质干细胞的存活率，增强间充质干细胞的治疗效果。
Description
技术领域
本发明属于药物技术，涉及一种增效干细胞治疗心梗的药物及其应用，具体为2-脱氧-D-葡萄糖在制备增效干细胞治疗心梗的药物中的应用。
背景技术
心肌梗死（MI）是一种严重危害人类健康的心血管疾病，随着我国人民生活水平的不断提高，缺血性心肌梗死的发病率也在不断上升。缺血性心肌梗死会导致心肌细胞坏死和瘢痕形成，进而影响心脏功能。目前药物或器械治疗大多只能缓解症状，但却不能逆转心脏组织损伤。心脏移植虽能彻底改善心脏状态，但因供体来源稀缺、免疫排斥以及昂贵的治疗费用等因素，在临床上很难广泛应用。
干细胞是一系列未分化的细胞，具有分化成特定细胞类型的能力。干细胞按来源可分为胚胎干细胞(Embryonic stem cells, ESC)和成体干细胞。后者包括造血干细胞(Hematopoietic stem cells, HSCs)和间充质干细胞(Mesenchymal stem cells, MSCs)。间充质干细胞几乎存在于人体所有具有特定干细胞龛位的组织中。骨髓来源的间充质干细胞(BM-MSCs)是第一个被发现的间充质干细胞，也是目前最多的用于心梗治疗的干细胞。但是现有技术表明，仅仅依靠干细胞治疗心梗，效果还需改善。
发明内容
2-脱氧-D-葡萄糖（2-DG）是一种葡萄糖类似物，具有干扰病毒特异性糖蛋白的合成、抑制疱疹单病毒、RAN和DNA包膜病毒、癌症细胞增殖等功效；但迄今为止尚未见2-脱氧-D-葡萄糖在心肌梗死方面的研究报道，尤其未见2-DG与干细胞作用关系的研究。
本发明公开了一种利用2-脱氧-D-葡萄糖改善心梗后干细胞治疗效果的新用途。MSCs治疗心梗的最大问题是移植细胞在心梗部位的滞留率低、存活性差。本发明公开了2-脱氧-D-葡萄糖对心肌梗死后间充质干细胞的治疗效果有明显提升。
本发明采用如下技术方案：
2-脱氧-D-葡萄糖在制备增效干细胞治疗心梗的药物中的应用。
2-脱氧-D-葡萄糖在制备治疗心梗的药物中的应用。
2-脱氧-D-葡萄糖和干细胞在制备增效治疗心梗的药物中的应用。
一种增效治疗心梗的药物，其活性成分为2-脱氧-D-葡萄糖和干细胞。还公开了该增效治疗心梗的药物在制备治疗心梗的药物中的应用。
本发明涉及的2-DG在制备预防或治疗心梗药物或保健品中的应用，具体的是2-DG可用于制备心梗保护药物、保健品或者食品，实现2-脱氧-D-葡萄糖尤其是增效干细胞，特别是间充质干细胞改善心梗后心功能、减缓心梗后心室扩张、减小心梗面积的技术效果。
本发明公开的制备的药物，具体的给药方式可采取腹腔注射等，2-脱氧-D-葡萄糖的给药量为300～800mg/kg/天，比如500 mg/kg/天。
考虑到MSCs的移植成功率，MI局部心肌内移植可能比静脉注射或冠状动脉内移植更为优越，但无论采用何种移植途径，最终目的仍然是优化策略，以增强注射的MSCs的存活率。现有技术下，由于MI导致心脏部位环境的复杂，使得现有间充质干细胞注射治疗心梗的效果欠佳，研究者采用各种方法以提高其对心梗的治疗效果，比如体外采用细胞因子培养间充质干细胞后回输等，此方法操作复杂。心肌梗死是一种严重危害人类健康的心血管疾病，随着我国人民生活水平的不断提高，缺血性心肌梗死的发病率也在不断上升。本发明首次采用2-脱氧-D-葡萄糖改善心梗后心功能，尤其是与间充质干细胞结合，增加干细胞治疗心梗的效果，减小心梗面积，从而可以预防或者治疗心梗。
附图说明
图1为2-DG改善MSCs治疗心梗后小鼠的心功能；
图2为2-DG改善MSCs治疗心梗后小鼠的心室重构；
图3为2-DG明显增加移植MSCs存活。
具体实施方式
以下所列实施例，仅为帮助本领域技术人员更全面理解本发明，但不以任何方式限制本发明。本发明涉及的原料试剂以及建模、测试都是本领域常规技术。
所使用的主要材料和来源分别如下：
C57BL/6J小鼠（昭衍（苏州）新药研究中心提供，此实验由苏州大学伦理委员会批准）；小动物呼吸机（上海奥尔科特生物科技有限公司，上海）；手术器械（六六视觉公司，苏州）；缝合针线（上海浦东金环医疗用品有限公司，上海）；小动物超声影像系统（VisualSonics Vevo 2100）；间充质干细胞（MSCs），采用现有技术从8周雄性C57BL/6J小鼠股骨骨髓中提取，常规培养第六代以后用于实验；2-脱氧-D-葡萄糖（2-DG，苏州天可贸易有限公司，苏州），溶于生理盐水（浓度为31.25mg/mL），备用。
小鼠心肌梗死模型的建立
选用25g左右的C57BL/6J雄性小鼠为实验对象，采用左冠状动脉前降支结扎法制作心梗模型。腹腔注射麻醉后，经口气管插管，接空气呼吸机，呼吸频率110次/min，潮气量2.5ml，吸呼比1:1.3。右侧卧位，左胸纵切口切开外层皮肤，剥离胸大肌，第三、四肋间横切口开胸，暴露心脏，用镊子撕开心包膜。借助手术显微镜可见左冠状动脉大致走行。在左心耳下缘约1.5mm处，将冠状动脉前降支（LAD） 连同少量心肌组织一起结扎，进针深度约1mm，宽度控制在3 mm以内；逐层关胸。
假手术组仅穿过LAD下方不打结，其余同模型组。
结扎后肉眼可见结扎处至心尖变白，1 周后取左心室组织进行心脏组织染色，可看到明显的纤维化，证明心梗模型建立成功。
MSCs组在结扎LAD后当即在心梗边缘区分三点注射提取的MSCs，注射细胞总数量为5x105/20 μl PBS；2-DG组仅在心梗建立前6h、心梗术后第1天、术后第2天腹腔注射2-DG（500 mg/kg/天）；MSCs+2-DG组在心梗建立前6h、心梗术后第1天、术后第2天腹腔注射2-DG（500 mg/kg/天），其余同MSCs组；对照组（生理盐水组）小鼠在结扎LAD后注射等量无菌生理盐水作为对照；三组喂养方式一致，然后进行心梗后心功能、心梗面积检测。
实施例1 有效改善心梗后心功能
心脏超声检测心梗后心功能。小鼠麻醉（方法同前），脱毛后左侧卧位，将心脏超声诊断仪探头置于心前壁，于乳头肌水平取左室二维短轴观，同时记录M型扫描，连续3个心动周期测量左室射血分数（EF）、缩短分数（FS）和左室舒张末径（LVEDD）和左室收缩末径（LVESD）。实验结果见图1，* P < 0.05；# P < 0.05。
实施例2 有效改善心室重构
心脏重量Masson染色：术后28天处死小鼠，测量小鼠体重（body weight，BW）、心脏重量（heart weight，HW）；计算HW/BW。Masson染色：术后28天处死小鼠，取左心室组织进行心脏组织染色，观察治疗效果。按常规Masson染色步骤进行，在普通光学显微镜下观察并拍照。采用图像分析软件Image J分析各部分面积，计算心梗面积/心脏面积。实验结果见图2，*P < 0.05，**P < 0.01。
实施例3 增加间充质干细胞存活
制备CM-DiI染色的间充质干细胞，利用CM-DiI的红色荧光特性观察移植间充质干细胞的存活率。具体的，配置CM-DiI染色工作液：CM-DiI染料储存液（赛默飞世尔）浓度为1mg/mL，取4uL储存液加到2mL PBS中，使终浓度为2ug/mL。取拟注射的MSCs（500000个），常规离心后用CM-DiL染色工作液重悬，37℃下孵育5min，再放入 4℃下放置 15 分钟，然后用PBS彻底清洗3遍，加入20uL PBS重悬用于心梗后心肌内注射。
术后第3天取心脏制备冰冻切片，做肌钙蛋白的组织切片免疫荧光，绿色标记肌钙蛋白，红色标记CM-DiI，蓝色表示DAPI标记细胞核；术后第3天取心脏消化制备单细胞悬液，流式检测CM-DiI阳性细胞比例和数量。实验结果见图3，*P<0.05。
【结论】上述实验的结果综合证明：2-DG能有效提高MSCs改善心梗的功能。
以上所述仅是本发明的优选实施方式，应当指出：对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
Claims (5)
1.2-脱氧-D-葡萄糖在制备增效间充质干细胞治疗心梗的药物中的应用；所述药物为注射制剂。
2.根据权利要求1所述的应用，其特征在于，2-脱氧-D-葡萄糖改善心梗后间充质干细胞治疗的心功能与心室重构。
3.2-脱氧-D-葡萄糖和间充质干细胞在制备增效治疗心梗的药物中的应用，其特征在于，所述药物为注射制剂。
4.2-脱氧-D-葡萄糖在制备增加间充质干细胞在心梗部位存活率的药物中的应用，其特征在于，所述药物为注射制剂。
5.一种药物在制备治疗心梗的药物中的应用，其特征在于，所述药物的活性成分为2-脱氧-D-葡萄糖和间充质干细胞；所述药物为注射制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110700458.8A CN113425731B (zh) | 2021-06-23 | 2021-06-23 | 一种增效干细胞治疗心梗的药物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110700458.8A CN113425731B (zh) | 2021-06-23 | 2021-06-23 | 一种增效干细胞治疗心梗的药物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113425731A CN113425731A (zh) | 2021-09-24 |
| CN113425731B true CN113425731B (zh) | 2022-09-23 |
Family
ID=77753584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110700458.8A Active CN113425731B (zh) | 2021-06-23 | 2021-06-23 | 一种增效干细胞治疗心梗的药物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113425731B (zh) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105395571A (zh) * | 2015-12-31 | 2016-03-16 | 苏州大学 | 间充质干细胞分泌的外泌小体治疗心肌梗死的新用途 |
| KR102002671B1 (ko) * | 2016-11-11 | 2019-07-23 | 사회복지법인 삼성생명공익재단 | 2ｄｇ를 이용한 줄기세포 역량 향상 방법 |
-
2021
- 2021-06-23 CN CN202110700458.8A patent/CN113425731B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113425731A (zh) | 2021-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112639076A (zh) | 促进细胞生长和组织修复的方法及组合物 | |
| CN108486046B (zh) | 一种抗缺氧损伤的干细胞制剂及其制备方法与在制备治疗急性心梗药物中的应用 | |
| CN108567775B (zh) | 硫辛酸在制备治疗压力负荷性心肌损伤的药物组合物中的应用 | |
| US20220347346A1 (en) | Mesenchymal stem cell sheet and use thereof | |
| US20200376037A1 (en) | Stem cell preparation resisting hypoxia injury, preparation method therefor, and use thereof in preparation of medicament for treating acute myocardial infarction | |
| CN106138081A (zh) | 一种靶向circRNA的药物组合物及其用途 | |
| CN113425731B (zh) | 一种增效干细胞治疗心梗的药物及其应用 | |
| WO2023185085A1 (zh) | Pd1抑制剂在制备心脏成纤维细胞转分化抑制剂中的用途 | |
| CN108904782A (zh) | Ctrp3用于制备预防治疗心肌肥厚药物的应用 | |
| US20240108658A1 (en) | Synergistic stem cell-based medication for treating myocardial infarction and related application | |
| CN113855650B (zh) | 一种免疫代谢心梗贴片及其制备方法与应用 | |
| CN107625781B (zh) | miRNA抑制子在制备防治心肌梗死药物中的应用 | |
| WO2004045666A1 (ja) | 臓器の再生方法 | |
| CN111184743B (zh) | 多类型混合细胞在心肌梗死细胞治疗中的应用 | |
| CN107296806A (zh) | 丹酚酸a作为脂蛋白相关磷脂酶a2抑制剂的新用途 | |
| RU2322248C2 (ru) | Способ лечения хронических заболеваний (варианты), способ получения биотрансплантата (варианты), биотрансплантат (варианты) | |
| CN111345917A (zh) | 小鼠心肌梗死后的心肌注射造模方法及装置 | |
| CN115998737B (zh) | 阿莫地喹在制备治疗压力负荷性心肌损伤的药物中的应用 | |
| CN111388761A (zh) | 天麻素在糖尿病环境中医用钛金属使用中的应用 | |
| CN113476462A (zh) | 一种防治心肌缺血后心功能衰竭的药物及其应用 | |
| CN115463134B (zh) | 一种sirt2特异性抑制剂ak-1的应用 | |
| CN114917346B (zh) | 用于缺血性心脏病治疗的药物及药物组合物 | |
| WO2023044689A1 (zh) | 一种免疫代谢心梗贴片及其制备方法与应用 | |
| CN117180435A (zh) | Frizzled 2作为靶点在治疗压力超负荷性心肌损伤中的作用 | |
| WO2023023995A1 (zh) | 一种防治心肌缺血后心功能衰竭的药物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |